Recent News

By Category: Countermeasures

Health Experts Narrow the Hunt for Ebola

(Infection Control Today)Response efforts to outbreaks of Ebola hemorrhagic fever in Africa can benefit from a standardized sampling strategy that focuses on the carcasses of gorillas, chimpanzees and other species known to succumb to the virus, according to a consortium of wildlife health experts.

May 18, 2012
| Filed under Africa, North America, Countermeasures, International, Policy & Initiatives, and Research
Share

Fuel ‘crisis’ hampers anthrax vaccination exercise

(Ghana Broadcasting Corporation) The Upper East Regional Director of Veterinary Service, Dr. Thomas Anyorikeya says, the main challenge facing the vaccination of animals in the area following the outbreak of anthrax is how to fuel vehicles to move into communities. Dr. Anyorikeya said though his outfit has presented budget to that effect only one District Read More »

May 18, 2012
| Filed under Africa, Agriculture, Countermeasures, and Policy & Initiatives
Share

Inovio Pharmaceuticals’ Universal Avian Flu Vaccine Generates Protective …

(MarketWatch) Inovio Pharmaceuticals, Inc. announced today that its SynCon® avian influenza vaccine generated protective HAI titers against six different unmatched strains of H5N1 in a phase I clinical trial – a distinct clinical achievement on Inovio’s path to develop universal influenza vaccines. By design, Inovio’s SynCon® flu vaccine is not matched to any single virus.

May 17, 2012
| Filed under North America, Countermeasures, and Public Health
Share

Evaluation of a genetically modified foot-and-mouth disease virus vaccine candidate generated by reverse genetics

(Press Release) Foot-and-mouth disease (FMD) is the most economically important and highly contagious disease of cloven-hoofed animals worldwide. Control of the disease has been mainly based on large-scale vaccinations with whole-virus inactivated vaccines. In recent years, a series of outbreaks of type O FMD occurred in China (including Chinese Taipei, Chinese Hong Kong) posed a Read More »

May 17, 2012
| Filed under Asia/Pacific, Agriculture, Countermeasures, and Research
Share

Phase I enrollment for A/H5N1 influenza vaccine trial begins

(Vaccine News Daily) Novavax, Inc., a Rockville, Maryland-based clinical-stage biopharmaceutical company, has started enrollment for its second phase I clinical trial for a monovalent virus-like particle vaccine candidate against A/H5N1 avian influenza viruses. The placebo-controlled, dose-ranging, observer blind, randomized trial is being conducted as part of Novavax’s contract with the Biomedical Advanced Research and Development Read More »